Thermo Fisher Scientific TMO Issuance of common stock for the acquisition of Ansys

Issuance of common stock for the acquisition of Ansys at other companies

WAT

Waters CorporationWAT

——

Revenue$11.0B+6.2%

Operating income$1.9B+8.6%

Net income$1.7B+9.6%

EPS (diluted)$4.43+11.3%

Cash & equivalents$3.3B-21.4%

Total debt$43.2B+16.6%

Total equity$51.9B+5.1%

Total assets$113.28B+14.4%

Operating cash flow$1.2B+64.9%

CapEx$376.0M+3.9%

Free cash flow$816.0M+126%

Market cap$172.66B-2.7%

Enterprise value$212.54B+0.9%

P/E25.2×-2.0×

P/S4×-0.8×

Gross margin58.3%—

Operating margin17.2%+0.8pp

Net margin15.2%+1.0pp

Return on equity13.5%-0.2pp

Debt / equity0.8×+0.1×

Current ratio1.5×-0.2×

Reported directly by Thermo Fisher Scientific in its filing.

Tagged under the XBRL concept us-gaap:StockIssued1.

The official record: Thermo Fisher Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Thermo Fisher Scientific's issuance of common stock for the acquisition of ansys?: Thermo Fisher Scientific (TMO) reported issuance of common stock for the acquisition of ansys of $62M in Q1 2026.
How has Thermo Fisher Scientific's issuance of common stock for the acquisition of ansys changed year-over-year?: Thermo Fisher Scientific's issuance of common stock for the acquisition of ansys decreased by 4.6% year-over-year, from $65M to $62M.